Sectoral Asset Management, Inc. is an employee-owned investment management firm specializing in the healthcare sector. Founded in 2000 and headquartered in Montreal, with additional offices in Geneva and Hong Kong, the company focuses on managing global investment portfolios, primarily for investment companies, pooled investment vehicles, banking institutions, and high net worth individuals. Sectoral emphasizes late-stage private equity investments and manages separate client-focused equity portfolios, including equity mutual funds and hedge funds. The firm employs a bottom-up stock picking approach, primarily investing in small-cap companies within the biotechnology and healthcare sectors, utilizing both in-house and external research. It also adopts a long-short strategy for its hedge funds, benchmarking performance against various indices. Sectoral Asset Management currently manages approximately $4 billion in assets, positioning itself as a leader in healthcare investment management.
Shoulder Innovations is a medical device company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry. The company's Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. It also leverages this technology to create simple surgical instrumentation, which reduces operative time and cost. Shoulder Innovations designs and commercializes innovative products that demonstrate the potential for improved patient care and reduced overall cost to the healthcare system. Published results show Shoulder Innovations’ solution provides greater post-surgical implant stability, addressing the leading cause of revision surgery.
Evommune
Series C in 2024
Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.
LENZ Therapeutics
Post in 2024
LENZ Therapeutics is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapies aimed at improving vision. The company's primary focus is on addressing presbyopia, a common condition that leads to the gradual loss of near vision, affecting nearly all individuals over the age of 45. LENZ Therapeutics is currently advancing an aceclidine-based eye drop specifically designed to restore near vision, addressing a significant unmet need in the market. Through its efforts, the company aims to enhance the quality of life for individuals experiencing vision changes related to aging.
Phagenesis
Series D in 2024
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "cortical remapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.
Cagent Vascular
Series C in 2024
Cagent Vascular, LLC is a medical device company based in Wayne, Pennsylvania, focused on developing innovative solutions for cardiovascular diseases. The company specializes in angioplasty balloons that utilize proprietary serration technology to enhance treatment outcomes. Its flagship product, the Serranator, features serrated metal strips embedded in a semi-compliant balloon, designed specifically for the treatment of atherosclerosis and conditions such as peripheral artery disease and chronic limb-threatening ischemia. By employing a minimally invasive approach, Cagent Vascular aims to improve vessel dilatation during cardiovascular interventions, ultimately enhancing patient care and quality of life. Founded in 2014, the company is dedicated to advancing intravascular technology in the medical field.
Noctrix Health
Series C in 2024
Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on restless leg syndrome. Its innovative device utilizes neural circuitry to alleviate symptoms and promote undisturbed sleep, empowering patients to better manage their chronic medical conditions.
CurvaFix
Series C in 2023
CurvaFix, Inc. is a medical device company based in Bellevue, Washington, founded in 2017. The company focuses on developing innovative solutions for orthopedic trauma, specifically targeting pelvic fractures. Its flagship product, The CurvaFix, is an intramedullary rod screw designed to conform to the natural curvature of bones, effectively filling the space within curved structures such as the pelvis. By enabling surgeons to perform simpler and shorter procedures, CurvaFix aims to enhance patient recovery outcomes in the treatment of pelvic injuries.
Boundless Bio
Series C in 2023
Boundless Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of aggressive cancers linked to extrachromosomal DNA (ecDNA). Founded in 2018 and based in La Jolla, California, the company aims to address the significant unmet medical needs of patients with oncogene amplified tumors, which affect over 14% of cancer patients. By targeting ecDNA, a key factor in oncogene amplification, Boundless Bio seeks to provide transformative treatments for previously difficult-to-treat cancers. One of its leading candidates, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), designed to manage the replication and transcription of ecDNA in cancer cells.
LENZ Therapeutics
Series B in 2023
LENZ Therapeutics is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapies aimed at improving vision. The company's primary focus is on addressing presbyopia, a common condition that leads to the gradual loss of near vision, affecting nearly all individuals over the age of 45. LENZ Therapeutics is currently advancing an aceclidine-based eye drop specifically designed to restore near vision, addressing a significant unmet need in the market. Through its efforts, the company aims to enhance the quality of life for individuals experiencing vision changes related to aging.
Garuda Therapeutics
Series B in 2023
Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.
Miach Orthopaedics
Series B in 2023
Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, founded in 2016. The company specializes in developing bio-engineered surgical implants aimed at facilitating new tissue growth and aiding in connective tissue repair. Its primary product, the Bridge-Enhanced ACL Repair technology, offers a viable alternative to traditional anterior cruciate ligament (ACL) reconstruction for patients who have suffered ACL injuries. This innovative approach enables surgeons to restore the normal anatomy and function of the knee, enhancing recovery outcomes for patients.
Amolyt Pharma
Series C in 2023
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.
Apnimed
Series C in 2022
Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, Apnimed aims to address the underlying neurobiological mechanisms that contribute to obstructive sleep apnea (OSA), a serious condition affecting over 20 million Americans. Current treatments, such as CPAP devices and surgical options, primarily manage symptoms rather than the root causes of the disorder. Apnimed's therapeutics are designed to provide a simple, safe, and effective oral treatment that targets both the physiological and symptomatic effects of OSA, offering a potential alternative to existing interventions.
Iantrek
Series B in 2022
Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York.
Mineralys Therapeutics
Series B in 2022
Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.
Apnimed
Series C in 2022
Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, Apnimed aims to address the underlying neurobiological mechanisms that contribute to obstructive sleep apnea (OSA), a serious condition affecting over 20 million Americans. Current treatments, such as CPAP devices and surgical options, primarily manage symptoms rather than the root causes of the disorder. Apnimed's therapeutics are designed to provide a simple, safe, and effective oral treatment that targets both the physiological and symptomatic effects of OSA, offering a potential alternative to existing interventions.
Magnolia Medical Technologies
Venture Round in 2022
Magnolia Medical Technologies, Inc. is a Seattle-based company that specializes in developing medical devices aimed at enhancing the accuracy of diagnostic blood culture tests. The company's flagship product, SteriPath, is a vacuum-assisted blood collection system designed to eliminate contamination from initial blood samples, thereby reducing false-positive results that can lead to misdiagnosis of conditions like sepsis. This innovative system employs a pre-assembled and sterile collection method that actively diverts potentially contaminated blood, allowing for the collection of uncontaminated samples through a separate pathway. By improving the quality of diagnostic specimens, Magnolia Medical Technologies seeks to enhance patient outcomes, lower hospital costs, and address the growing issue of antibiotic resistance. The company, incorporated in 2011, also holds a substantial intellectual property portfolio, which includes over 70 issued patents and more than 50 additional patent applications pending.
Prilenia
Series B in 2021
Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018, the company operates from locations in Israel, the Netherlands, and Boston. Its primary asset is Pridopidine, an oral drug candidate that has demonstrated an established safety profile and shows promise in treating various movement disorders and neurodegenerative diseases in both adults and children. Prilenia aims to enhance the functional capacity of patients, particularly those undergoing early hemodialysis, by addressing the underlying challenges posed by these conditions.
Better Therapeutics
Post in 2021
Better Therapeutics is a company focused on the discovery, development, and commercialization of prescription digital therapeutics aimed at treating cardiovascular and metabolic diseases. It utilizes clinically validated, FDA-regulated software to promote behavior changes that address the underlying causes of these conditions, thereby enhancing quality of life, reducing reliance on medications, and lowering healthcare costs. The company's offerings include digital behavioral therapy that combines neuroscience, lifestyle medicine, and explainable artificial intelligence through a physician-prescribed mobile medical app. This approach leverages patient-generated data to guide clinical decision-making and optimize treatment outcomes. Better Therapeutics' current product pipeline features therapeutic candidates targeting type 2 diabetes, hypertension, and dyslipidemia.
Babylon
Post in 2021
Babylon is a digital-first, value-based care company. Founded in 2013, it aims to make high-quality healthcare accessible and affordable for everyone on Earth. It reengineers the global healthcare market to better align system-wide incentives and to shift the focus from reactive sick care to preventative healthcare, resulting in better member health, improved member experience and reduced costs. To achieve this goal, it leverages its highly scalable, digital-first platform combined with high quality clinical operations and affiliated provider networks to provide an integrated, end-to-end healthcare solution.
Garuda Therapeutics
Series A in 2021
Garuda Therapeutics is a biotech company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening diseases, particularly those affecting blood, bone marrow, immunity, and metabolism. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants by leveraging its innovative platform technology to generate self-renewing blood stem cells. This approach is designed to ensure rapid and broad access to consistent, durable, HLA-compatible, and transgene-free blood stem cell therapies for patients. Garuda Therapeutics employs advanced methodologies, including the use of zebrafish, mice, and human-induced pluripotent stem cells, to clone and analyze novel genes and mechanisms critical for blood formation, ultimately developing mechanism-based therapies that address unmet medical needs.
Amolyt Pharma
Series B in 2021
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.
Effector Therapeutics
Post in 2021
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.
Turnstone Biologics
Series D in 2021
Turnstone Biologics Inc. is a biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, it is dedicated to developing innovative viral immunotherapies aimed at improving survival rates for cancer patients. The company's lead product, RIVAL-01, utilizes a vaccinia virus backbone to deliver three key immunomodulators: Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine. These components are designed to enhance immune activity and reprogram the tumor microenvironment for optimal tumor eradication. Additionally, Turnstone Biologics is advancing next-generation tumor-infiltrating lymphocyte (TIL) therapies, which involve selecting and expanding the most effective T cells from a patient’s tumor to enhance the body’s immune response against solid tumors. Through these approaches, Turnstone aims to deliver breakthrough immunotherapies for cancer treatment.
Viracta Therapeutics
Post in 2021
Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, focused on precision oncology for virus-associated malignancies. The company specializes in a viral activation therapy platform aimed at treating cancers linked to the Epstein-Barr Virus (EBV) and other virus-associated diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir in Phase 2 clinical trials for EBV-positive lymphoma, including conditions such as post-transplant lymphoproliferative disorder and plasmablastic lymphoma. Viracta is also exploring the application of this therapeutic approach in treating other EBV-related malignancies, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and previously known as HemaQuest Pharmaceuticals, Viracta Therapeutics continues to advance its mission to develop innovative treatments for serious viral-associated cancers.
Pipeline Therapeutics
Series C in 2021
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to the nervous system.
Neuros Medical
Series B in 2021
Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.
CurvaFix
Series B in 2020
CurvaFix, Inc. is a medical device company based in Bellevue, Washington, founded in 2017. The company focuses on developing innovative solutions for orthopedic trauma, specifically targeting pelvic fractures. Its flagship product, The CurvaFix, is an intramedullary rod screw designed to conform to the natural curvature of bones, effectively filling the space within curved structures such as the pelvis. By enabling surgeons to perform simpler and shorter procedures, CurvaFix aims to enhance patient recovery outcomes in the treatment of pelvic injuries.
Checkmate Pharmaceuticals
Series C in 2020
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.
Prilenia
Series A in 2020
Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018, the company operates from locations in Israel, the Netherlands, and Boston. Its primary asset is Pridopidine, an oral drug candidate that has demonstrated an established safety profile and shows promise in treating various movement disorders and neurodegenerative diseases in both adults and children. Prilenia aims to enhance the functional capacity of patients, particularly those undergoing early hemodialysis, by addressing the underlying challenges posed by these conditions.
Atea Pharmaceuticals
Series D in 2020
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that focuses on discovering and developing antiviral therapies for severe viral infections. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by SARS-CoV-2. Additionally, Atea is developing several other product candidates, including AT-787, which is in phase 2 trials for hepatitis C, and AT-752 for dengue. Other candidates, such as AT-889 and AT-934, are also in phase 2 clinical trials targeting respiratory syncytial virus. Established in 2014, Atea Pharmaceuticals aims to improve treatment options for patients suffering from serious viral infections.
Pipeline Therapeutics
Series B in 2019
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to the nervous system.
HighLife
Series B in 2019
HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating patients with mitral valve regurgitation. Co-founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve that can be implanted in a beating heart while preserving the native valve structure and surrounding anatomy. The innovative system allows for delivery through a transseptal passage via the femoral vein, enabling a reversible procedure that minimizes patient trauma during complex heart surgeries. HighLife's focus is on ensuring ease and safety of use, contributing to improved treatment outcomes for patients. The company's technology is currently undergoing clinical evaluation.
Aprea
Series C in 2018
Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.
Rainier Therapeutics
Series B in 2018
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.
Simplify Medical
Series B in 2018
Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.
Apellis Pharmaceuticals
Series E in 2017
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.
Effector Therapeutics
Series C in 2017
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.
Simplify Medical
Series B in 2017
Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.
ShockWave Medical
Series C in 2016
ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.
F2G
Venture Round in 2016
F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.
Aprea
Series B in 2016
Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.
Effector Therapeutics
Series B in 2016
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. Established in 2012, the company specializes in developing selective translation regulators for cancer and other serious diseases. Its innovative approach involves small molecule drugs known as selective translation regulator inhibitors (STRIs), which target the eIF4F complex and its associated kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). This complex plays a crucial role in the translation of specific messenger RNA into proteins linked to cancer progression. eFFECTOR's lead product candidate, tomivosertib, is currently being evaluated in a Phase 2b trial in combination with pembrolizumab for non-small cell lung cancer. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation trials with plans for further expansion. The company also collaborates with Pfizer to develop inhibitors targeting eIF4E. Through these efforts, eFFECTOR aims to address the challenges of tumor growth, survival, and immune evasion in cancer treatment.
Intellia Therapeutics
Series B in 2015
Intellia Therapeutics is a genome editing company headquartered in Cambridge, Massachusetts, that specializes in developing innovative therapeutics using the CRISPR/Cas9 technology. The company focuses on in vivo programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Additionally, Intellia's ex vivo pipeline includes engineered cell therapies aimed at treating various oncological and autoimmune diseases. The company has entered into collaborations with notable organizations, including Novartis and Regeneron Pharmaceuticals, to advance its research and development efforts. Founded in 2014, Intellia Therapeutics is committed to addressing severe and life-threatening diseases through its comprehensive intellectual property platform and a broad range of clinical development programs.
Advaxis
Post in 2015
Advaxis, Inc. is a clinical-stage biotechnology company based in Princeton, New Jersey, focused on developing innovative immunotherapies for cancer and infectious diseases. The company's therapies utilize a novel platform based on bio-engineered, live attenuated bacteria that secrete antigen/adjuvant fusion proteins to harness the immune system's response against cancer. Key products under development include axalimogene filolisbac (AXAL), which is in phase II trials for head and neck cancer, and ADXS-PSA for prostate cancer. Additionally, Advaxis is working on ADXS-NEO, which tailors immunotherapy based on a patient's tumor neoantigens, ADXS-HOT for boosting anti-cancer immunity, and ADXS-HER2, targeting HER2-expressing solid tumors. The company has established collaborations and licensing agreements with several organizations, enhancing its research capabilities and development efforts.
Cogent Biosciences
Series B in 2015
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.
REGENXBIO
Series D in 2015
REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy aimed at addressing genetic defects and enabling cells to produce therapeutic proteins and antibodies. The company utilizes its proprietary NAV Technology Platform, which involves recombinant adeno-associated virus vectors for gene delivery. REGENXBIO’s lead candidate, RGX-314, is currently in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Additional product candidates under development include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Beyond its own product candidates, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration agreement with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.
ShockWave Medical
Series B in 2015
ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.
Advaxis
Post in 2015
Advaxis, Inc. is a clinical-stage biotechnology company based in Princeton, New Jersey, focused on developing innovative immunotherapies for cancer and infectious diseases. The company's therapies utilize a novel platform based on bio-engineered, live attenuated bacteria that secrete antigen/adjuvant fusion proteins to harness the immune system's response against cancer. Key products under development include axalimogene filolisbac (AXAL), which is in phase II trials for head and neck cancer, and ADXS-PSA for prostate cancer. Additionally, Advaxis is working on ADXS-NEO, which tailors immunotherapy based on a patient's tumor neoantigens, ADXS-HOT for boosting anti-cancer immunity, and ADXS-HER2, targeting HER2-expressing solid tumors. The company has established collaborations and licensing agreements with several organizations, enhancing its research capabilities and development efforts.
Endosense
Series C in 2013
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
RainDance Technologies
Series E in 2013
RainDance Technologies, based in Billerica, Massachusetts, specializes in developing genomic tools for non-invasive liquid biopsy applications focused on the research, early detection, and treatment of cancer, as well as other inherited and infectious diseases. The company offers a range of innovative products, including the RainDrop digital polymerase chain reaction platform, which utilizes picoliter-sized droplets for multiplex detection of various genetic materials. Additionally, RainDance provides the ThunderStorm automated next-generation sequencing content enrichment solution, and the ThunderBolts NGS panels, designed for profiling significant cancer mutations and targeting genes associated with myeloid disorders. Through its advanced droplet technology, RainDance enables research institutions and laboratories to conduct precise genetic analysis, facilitating the understanding of complex genetic variations. Founded in 2004, the company operates as a subsidiary of Bio-Rad Laboratories and serves a global market through sales representatives and distributors.
Endosense
Series C in 2012
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
Endosense
Series B in 2009
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
BioVex
Venture Round in 2009
BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.